Investment Analysts’ Weekly Ratings Updates for Autolus Therapeutics (AUTL)

Several analysts have recently updated their ratings and price targets for Autolus Therapeutics (NASDAQ: AUTL):

• 8/16/2026 – Autolus Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/13/2026 – Autolus Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 8/8/2026 – Autolus Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 8/3/2026 – Autolus Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
• 7/31/2026 – Autolus Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 7/6/2026 – Autolus Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.